Next Article in Journal
CDCP1 Expression Is a Potential Biomarker of Poor Prognosis in Resected Stage I Non-Small-Cell Lung Cancer
Next Article in Special Issue
Platelet-Derived Drug Targets and Biomarkers of Ischemic Stroke—The First Dynamic Human LC-MS Proteomic Study
Previous Article in Journal
Comparative Analysis of Root Canal Dentin Removal Capacity of Two NiTi Endodontic Reciprocating Systems for the Root Canal Treatment of Primary Molar Teeth. An In Vitro Study
Previous Article in Special Issue
The Role of Factor Xa-Independent Pathway and Anticoagulant Therapies in Cancer-Related Stroke
 
 
Article

New Candidates for Biomarkers and Drug Targets of Ischemic Stroke—A First Dynamic LC-MS Human Serum Proteomic Study

1
Department of Neurology, 4th Military Hospital, Weigla 5, 50-556 Wroclaw, Poland
2
Institute of Biochemistry and Biophysics, Polish Academy of Sciences, Pawińskiego 5a, 02-106 Warszawa, Poland
3
Lower Silesian Centre for Lung Diseases, Grabiszyńska 105, 53-439 Wroclaw, Poland
4
Department of Internal Medicine, Hypertension and Clinical Oncology, Wroclaw Medical University, Borowska 213, 50-556 Wroclaw, Poland
5
Department of Pharmacology, Faculty of Medicine, Wroclaw Medical University, Mikulicz-Radecki 2, 50-349 Wroclaw, Poland
*
Author to whom correspondence should be addressed.
Academic Editors: Maria Luisa Zedde and Rosario Pascarella
J. Clin. Med. 2022, 11(2), 339; https://doi.org/10.3390/jcm11020339
Received: 18 November 2021 / Revised: 6 January 2022 / Accepted: 10 January 2022 / Published: 11 January 2022
(This article belongs to the Special Issue New Frontiers in the Clinical Management of Stroke)
(1) Background: The aim of this dynamic-LC/MS-human-serum-proteomic-study was to identify potential proteins-candidates for biomarkers of acute ischemic stroke, their changes during acute phase of stroke and to define potential novel drug-targets. (2) Methods: A total of 32 patients (29–80 years) with acute ischemic stroke were enrolled to the study. The control group constituted 29 demographically-matched volunteers. Subjects with stroke presented clinical symptoms lasting no longer than 24 h, confirmed by neurological-examination and/or new cerebral ischemia visualized in the CT scans (computed tomography). The analysis of plasma proteome was performed using LC-MS (liquid chromatography–mass spectrometry). (3) Results: Ten proteins with significantly different serum concentrations between groups volunteers were: complement-factor-B, apolipoprotein-A-I, fibronectin, alpha-2-HS-glycoprotein, alpha-1B-glycoprotein, heat-shock-cognate-71kDa protein/heat-shock-related-70kDa-protein-2, thymidine phosphorylase-2, cytoplasmic-tryptophan-tRNA-ligase, ficolin-2, beta-Ala-His-dipeptidase. (4) Conclusions: This is the first dynamic LC-MS study performed on a clinical model which differentiates serum proteome of patients in acute phase of ischemic stroke in time series and compares to control group. Listed proteins should be considered as risk factors, markers of ischemic stroke or potential therapeutic targets. Further clinical validation might define their exact role in differential diagnostics, monitoring the course of the ischemic stroke or specifying them as novel drug targets. View Full-Text
Keywords: ischemic stroke; biomarker; therapeutic target; proteomics; liquid chromatography–mass spectrometry (LC-MS) ischemic stroke; biomarker; therapeutic target; proteomics; liquid chromatography–mass spectrometry (LC-MS)
Show Figures

Figure 1

MDPI and ACS Style

Turek-Jakubowska, A.; Dębski, J.; Jakubowski, M.; Szahidewicz-Krupska, E.; Gawryś, J.; Gawryś, K.; Janus, A.; Trocha, M.; Doroszko, A. New Candidates for Biomarkers and Drug Targets of Ischemic Stroke—A First Dynamic LC-MS Human Serum Proteomic Study. J. Clin. Med. 2022, 11, 339. https://doi.org/10.3390/jcm11020339

AMA Style

Turek-Jakubowska A, Dębski J, Jakubowski M, Szahidewicz-Krupska E, Gawryś J, Gawryś K, Janus A, Trocha M, Doroszko A. New Candidates for Biomarkers and Drug Targets of Ischemic Stroke—A First Dynamic LC-MS Human Serum Proteomic Study. Journal of Clinical Medicine. 2022; 11(2):339. https://doi.org/10.3390/jcm11020339

Chicago/Turabian Style

Turek-Jakubowska, Aleksandra, Janusz Dębski, Maciej Jakubowski, Ewa Szahidewicz-Krupska, Jakub Gawryś, Karolina Gawryś, Agnieszka Janus, Małgorzata Trocha, and Adrian Doroszko. 2022. "New Candidates for Biomarkers and Drug Targets of Ischemic Stroke—A First Dynamic LC-MS Human Serum Proteomic Study" Journal of Clinical Medicine 11, no. 2: 339. https://doi.org/10.3390/jcm11020339

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop